Clinical Trials Logo

cGVHD clinical trials

View clinical trials related to cGVHD.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06244628 Recruiting - cGVHD Clinical Trials

Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

Start date: January 10, 2024
Phase: Phase 3
Study type: Interventional

This is a randomized, single-center phase 3 clinical trial without blinding. Iguratimod, as a rheumatoid arthritis medication, is used to treat autoimmune diseases such as Sjögren's syndrome. It has acceptable side effects, good clinical availability, and is cost-effective. The investigators plan to recruit participants for a clinical trial to evaluate the efficacy and safety of Iguratimod in the treatment of chronic GVHD.

NCT ID: NCT06186804 Recruiting - cGvHD Clinical Trials

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Start date: May 30, 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, single arm, open label phase II clinical study in China. This study will evaluate the efficacy and safety of ABSK021 (Pimicotinib) in the treatment of patients with cGvHD who failed first-line therapy.

NCT ID: NCT05919511 Recruiting - cGVHD Clinical Trials

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

THRIVE
Start date: August 2, 2023
Phase:
Study type: Observational

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

NCT ID: NCT05214066 Recruiting - aGVHD Clinical Trials

Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT

Start date: February 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of combined ATG #antithymocyte globulin # regimen (5mg/kg divided from day -5 to day -2) for aGVHD(acute graft-versus-host disease ) prophylaxis in matched sibling donor peripheral blood stem cell transplantation (MSD-PBSCT).